RAPT THERAPEUTICS INC

RAPT Therapeutics Reports First Quarter 2023 Financial Results

11 May 2023 08:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

03 May 2023 08:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 16:19:49 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

29 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

14 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

07 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

08 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

30 Nov 2022 19:05:22 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

17 Nov 2022 21:38:04 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

17 Nov 2022 16:24:51 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

10 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

09 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

28 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

31 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

11 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Private Placement Financing of $50 Million

25 May 2022 08:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

23 May 2022 08:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports First Quarter 2022 Financial Results

11 May 2022 08:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

04 May 2022 08:00:02 By Nasdaq GlobeNewswire